- Home
- ECOR vs SACH Comparison
ECOR vs SACH Comparison
Compare ECOR & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECOR
- SACH
- Stock Information
- Founded
- ECOR 2005
- SACH 2010
- Country
- ECOR United States
- SACH United States
- Employees
- ECOR N/A
- SACH 29
- Industry
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- SACH Real Estate Investment Trusts
- Sector
- ECOR Health Care
- SACH Real Estate
- Exchange
- ECOR Nasdaq
- SACH Nasdaq
- Market Cap
- ECOR 50.1M
- SACH 45.2M
- IPO Year
- ECOR 2018
- SACH 2017
- Fundamental
- Price
- ECOR $5.04
- SACH $0.99
- Analyst Decision
- ECOR Strong Buy
- SACH Hold
- Analyst Count
- ECOR 2
- SACH 3
- Target Price
- ECOR $25.50
- SACH $2.25
- AVG Volume (30 Days)
- ECOR 182.1K
- SACH 287.8K
- Earning Date
- ECOR 05-07-2025
- SACH 05-01-2025
- Dividend Yield
- ECOR N/A
- SACH 18.24%
- EPS Growth
- ECOR N/A
- SACH N/A
- EPS
- ECOR N/A
- SACH N/A
- Revenue
- ECOR $26,458,000.00
- SACH N/A
- Revenue This Year
- ECOR $26.76
- SACH N/A
- Revenue Next Year
- ECOR $44.87
- SACH $4.52
- P/E Ratio
- ECOR N/A
- SACH N/A
- Revenue Growth
- ECOR 41.54
- SACH N/A
- 52 Week Low
- ECOR $4.47
- SACH $0.80
- 52 Week High
- ECOR $19.49
- SACH $3.16
- Technical
- Relative Strength Index (RSI)
- ECOR 39.64
- SACH 53.80
- Support Level
- ECOR $4.77
- SACH $0.90
- Resistance Level
- ECOR $5.49
- SACH $1.00
- Average True Range (ATR)
- ECOR 0.44
- SACH 0.05
- MACD
- ECOR 0.08
- SACH 0.01
- Stochastic Oscillator
- ECOR 41.08
- SACH 98.74
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.